RUA Life Sciences plc

AIM:RUA Stock Report

Market Cap: UK£6.8m

RUA Life Sciences Management

Management criteria checks 4/4

RUA Life Sciences' CEO is Bill Brown, appointed in Jan 2024, has a tenure of less than a year. total yearly compensation is £286.05K, comprised of 90.7% salary and 9.3% bonuses, including company stock and options. directly owns 1.36% of the company’s shares, worth £92.61K. The average tenure of the management team and the board of directors is 2.9 years and 6.5 years respectively.

Key information

Bill Brown

Chief executive officer

UK£286.1k

Total compensation

CEO salary percentage90.7%
CEO tenureless than a year
CEO ownership1.4%
Management average tenure2.9yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

The Rua Life Sciences (LON:RUA) Share Price Is Up 481% And Shareholders Are Delighted

Feb 15
The Rua Life Sciences (LON:RUA) Share Price Is Up 481% And Shareholders Are Delighted

CEO Compensation Analysis

How has Bill Brown's remuneration changed compared to RUA Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

UK£206k

Jun 30 2024n/an/a

-UK£617k

Mar 31 2024UK£286kUK£259k

-UK£1m

Dec 31 2023n/an/a

-UK£2m

Sep 30 2023n/an/a

-UK£2m

Jun 30 2023n/an/a

-UK£2m

Mar 31 2023UK£297kUK£242k

-UK£2m

Dec 31 2022n/an/a

-UK£2m

Sep 30 2022n/an/a

-UK£2m

Jun 30 2022n/an/a

-UK£2m

Mar 31 2022UK£301kUK£230k

-UK£2m

Dec 31 2021n/an/a

-UK£2m

Sep 30 2021n/an/a

-UK£2m

Jun 30 2021n/an/a

-UK£2m

Mar 31 2021UK£237kUK£166k

-UK£1m

Dec 31 2020n/an/a

-UK£1m

Sep 30 2020n/an/a

-UK£1m

Jun 30 2020n/an/a

-UK£1m

Mar 31 2020UK£247kUK£175k

-UK£816k

Dec 31 2019n/an/a

-UK£679k

Sep 30 2019n/an/a

-UK£542k

Jun 30 2019n/an/a

-UK£575k

Mar 31 2019UK£180kUK£138k

-UK£609k

Dec 31 2018n/an/a

-UK£389k

Sep 30 2018n/an/a

-UK£170k

Jun 30 2018n/an/a

-UK£102k

Mar 31 2018UK£57kUK£57k

-UK£34k

Compensation vs Market: Bill's total compensation ($USD359.00K) is about average for companies of similar size in the UK market ($USD345.30K).

Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.

CEO

Bill Brown (61 yo)

less than a year

Tenure

UK£286,053

Compensation

Mr. William Donald Brown, also known as Bill, serves as Chief Executive at Rua Life Sciences Plc (formerly known as AorTech International plc) since 2024. He served as the Finance Director at Rua Life Scie...

Leadership Team

NamePositionTenureCompensationOwnership
William Brown
Chief Executiveless than a yearUK£286.05k1.36%
£ 92.6k
Lachlan Smith
CFO & Director2.9yrsUK£156.03k0.18%
£ 12.1k
Kathryn Full
Company Secretary5.9yrsno datano data

2.9yrs

Average Tenure

Experienced Management: RUA's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Brown
Chief Executive13.2yrsUK£286.05k1.36%
£ 92.6k
Lachlan Smith
CFO & Director2.8yrsUK£156.03k0.18%
£ 12.1k
Ian Ardill
Independent Non-Executive Director3.9yrsUK£40.60k0.44%
£ 30.0k
John Ely
Independent Non-Executive Director6.5yrsUK£41.35k0.0067%
£ 458.1
John McKenna
Non-Executive Director8.2yrsUK£80.35k0.18%
£ 12.1k
Geoffrey Berg
Independent Non-Executive Chairman6.5yrsUK£40.60k0.040%
£ 2.8k

6.5yrs

Average Tenure

64.5yo

Average Age

Experienced Board: RUA's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 19:45
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RUA Life Sciences plc is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew Murray DarleyCavendish
Christopher DonnellanCavendish
Christopher DonnellanCavendish Historical (Cenkos Securities)